FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170395917> ?p ?o ?g. }

• W3170395917 endingPage "2858" @default.
• W3170395917 startingPage "2858" @default.
• W3170395917 abstract "Antibodies targeting Immune Checkpoints (IC) on tumor infiltrating lymphocytes improve immune responses against cancer. Recently, the expression of some ICs has also been reported on cancer cells. We used the clinically validated Ipilimumab and Nivolumab and other novel human antibodies targeting Cytotoxic T- lymphocyte-antigen 4 (CTLA-4), Programmed Death receptor-1 (PD-1) and Programmed Death Ligand 1 (PD-L1) to shed light on the functions of these ICs in cancer cells. We show here for the first time that all these antagonistic mAbs are able to reduce Erk phosphorylation and, unexpectedly, to induce a significant increase of ICs expression on tumor cells, involving a hyperphosphorylation of NF-kB. On the contrary, agonistic PD-L1 and PD-1 recombinant proteins showed opposite effects by leading to a significant reduction of PD-1 and PD-L1, thus also suggesting the existence of a crosstalk in tumor cells between multiple ICs. Since the immunomodulatory mAbs show their higher anti-tumor efficacy by activating lymphocytes against cancer cells, we also investigated whether it was possible to identify the most efficient combinations of immunomodulatory mAbs for achieving potent anti-tumor efficacy associated with the lowest adverse side effects by setting up novel simple and predictive in vitro models based on co-cultures of tumor cells or human fetal cardiomyocytes with lymphocytes. We demonstrate here that novel combinations of immunomodulatory mAbs with more potent anti-cancer activity than Ipilimumab and Nivolumab combination can be identified with no or lower cardiotoxic side effects. Thus, we propose these co-cultures-based assays as useful tools to test also other combinatorial treatments of emerging immunomodulatory mAbs against different ICs for the early screening of most potent and safe combinatorial therapeutic regimens." @default.
• W3170395917 created "2021-06-22" @default.
• W3170395917 creator A5001436978 @default.
• W3170395917 creator A5018619706 @default.
• W3170395917 creator A5044575946 @default.
• W3170395917 creator A5049333472 @default.
• W3170395917 creator A5067435976 @default.
• W3170395917 creator A5082891817 @default.
• W3170395917 date "2021-06-08" @default.
• W3170395917 modified "2023-09-25" @default.
• W3170395917 title "Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments" @default.
• W3170395917 cites W1533279968 @default.
• W3170395917 cites W1671303963 @default.
• W3170395917 cites W1872543517 @default.
• W3170395917 cites W2001131198 @default.
• W3170395917 cites W2044200527 @default.
• W3170395917 cites W2066671159 @default.
• W3170395917 cites W2069754433 @default.
• W3170395917 cites W2097707681 @default.
• W3170395917 cites W2097995306 @default.
• W3170395917 cites W2100117872 @default.
• W3170395917 cites W2104764745 @default.
• W3170395917 cites W2114972737 @default.
• W3170395917 cites W2121988130 @default.
• W3170395917 cites W2129942624 @default.
• W3170395917 cites W2134012905 @default.
• W3170395917 cites W2156268588 @default.
• W3170395917 cites W2174658894 @default.
• W3170395917 cites W2179666906 @default.
• W3170395917 cites W2289712604 @default.
• W3170395917 cites W2334240824 @default.
• W3170395917 cites W2463159167 @default.
• W3170395917 cites W2510686645 @default.
• W3170395917 cites W2572843558 @default.
• W3170395917 cites W2586157991 @default.
• W3170395917 cites W2604821587 @default.
• W3170395917 cites W2606528598 @default.
• W3170395917 cites W2736166064 @default.
• W3170395917 cites W2759963646 @default.
• W3170395917 cites W2765354611 @default.
• W3170395917 cites W2789315292 @default.
• W3170395917 cites W2791483720 @default.
• W3170395917 cites W2793167197 @default.
• W3170395917 cites W2793180707 @default.
• W3170395917 cites W2801978619 @default.
• W3170395917 cites W2805215571 @default.
• W3170395917 cites W2866963304 @default.
• W3170395917 cites W2887577080 @default.
• W3170395917 cites W2888880602 @default.
• W3170395917 cites W2897523860 @default.
• W3170395917 cites W2897550585 @default.
• W3170395917 cites W2911491594 @default.
• W3170395917 cites W2945043419 @default.
• W3170395917 cites W2945219971 @default.
• W3170395917 cites W2946430473 @default.
• W3170395917 cites W2955890341 @default.
• W3170395917 cites W2963997426 @default.
• W3170395917 cites W2971259180 @default.
• W3170395917 cites W2972645775 @default.
• W3170395917 cites W2972996828 @default.
• W3170395917 cites W2981588267 @default.
• W3170395917 cites W2997135462 @default.
• W3170395917 cites W3002425056 @default.
• W3170395917 cites W3003539399 @default.
• W3170395917 cites W3011027479 @default.
• W3170395917 cites W3040249597 @default.
• W3170395917 cites W3043703771 @default.
• W3170395917 cites W3047539613 @default.
• W3170395917 cites W3093167997 @default.
• W3170395917 cites W3102097728 @default.
• W3170395917 cites W3108832674 @default.
• W3170395917 doi "https://doi.org/10.3390/cancers13122858" @default.
• W3170395917 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8230074" @default.
• W3170395917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34201082" @default.
• W3170395917 hasPublicationYear "2021" @default.
• W3170395917 type Work @default.
• W3170395917 sameAs 3170395917 @default.
• W3170395917 citedByCount "10" @default.
• W3170395917 countsByYear W31703959172021 @default.
• W3170395917 countsByYear W31703959172022 @default.
• W3170395917 countsByYear W31703959172023 @default.
• W3170395917 crossrefType "journal-article" @default.
• W3170395917 hasAuthorship W3170395917A5001436978 @default.
• W3170395917 hasAuthorship W3170395917A5018619706 @default.
• W3170395917 hasAuthorship W3170395917A5044575946 @default.
• W3170395917 hasAuthorship W3170395917A5049333472 @default.
• W3170395917 hasAuthorship W3170395917A5067435976 @default.
• W3170395917 hasAuthorship W3170395917A5082891817 @default.
• W3170395917 hasBestOaLocation W31703959171 @default.
• W3170395917 hasConcept C121608353 @default.
• W3170395917 hasConcept C126322002 @default.
• W3170395917 hasConcept C147483822 @default.
• W3170395917 hasConcept C154317977 @default.
• W3170395917 hasConcept C159654299 @default.
• W3170395917 hasConcept C202751555 @default.
• W3170395917 hasConcept C203014093 @default.
• W3170395917 hasConcept C2777701055 @default.
• W3170395917 hasConcept C2780030458 @default.

• next